RT @Janetbirdope: Who declines most with #scleroderma #ILD - early dcSSc, â¬ï¸CRP, â¬ï¸mRSS all w more ⤵ï¸FVC. Re
Tweet Content
Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Results verified in SENSIS trial of SSc ILD where #nintedanib was superior to placebo abst#1846 #ACR21 @RheumNow https://t.co/eckUj0qwch
Show on Archive Page
On
Display in Search Results
On
PDQ
Off